Supernus Pharmaceuticals
SUPN • NASDAQ
Supernus Pharmaceuticals is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Jack A. Khattar, with a market cap of $2.9B.
CEOJack A. Khattar
Next Earnings
Upcoming earnings announcement for Supernus Pharmaceuticals
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.20
Revenue Estimate
$191.2M
Earnings History
Past 12 earnings reports for Supernus Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | -$0.07Est: $0.22 | -131.8% | $211.6MEst: $195.8M | +8.1% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.80Est: $0.62 | -229.0% | $192.1MEst: $181.0M | +6.2% | 10-Q |
| Aug 5, 2025 | Q2 2025 | $0.40Est: $0.42 | -4.8% | $180.9MEst: $154.1M | +17.4% | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.21Est: $0.37 | -156.8% | $149.8MEst: $147.9M | +1.3% | 10-Q |
| Feb 25, 2025 | Q4 2024 | $0.27Est: $0.52 | -48.1% | $174.2MEst: $155.3M | +12.2% | 10-K |
| Nov 4, 2024 | Q3 2024 | $0.69Est: $0.44 | +56.8% | $175.7MEst: $157.3M | +11.7% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.36Est: $0.39 | -7.7% | $168.3MEst: $148.9M | +13.1% | 10-Q |
| May 8, 2024 | Q1 2024 | $0.00Est: $0.38 | -100.0% | $143.6MEst: $145.8M | -1.5% | 10-Q |
| Feb 27, 2024 | Q4 2023 | $0.39Est: $0.55 | -29.1% | $164.3MEst: $155.0M | +6.0% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.29Est: $0.13 | -323.1% | $153.9MEst: $146.1M | +5.3% | — |
| Aug 8, 2023 | Q2 2023 | -$0.02Est: -$0.23 | +91.3% | $135.6MEst: $144.4M | -6.1% | 10-Q |
| May 9, 2023 | Q1 2023 | $0.29Est: $0.17 | +70.6% | $153.8MEst: $139.0M | +10.6% | — |